Astute Doctor, Inc. , a developer of novel, biomarker-based medical diagnostics, today announced the completion of a $40 grant. 4 million Series C financing led by MPM Capital, including the new investor Kaiser Permanente Ventures The Company intends to use the proceeds to begin the commercialization of its first product and to advance and expand its research, development and validation of biomarker-based laboratory tests.
“Astute Medical has made rapid progress in developing biomarker-based diagnostics to address major unmet medical needs,” said Jim Scopa, Managing Director of MPM Capital. “We are excited to fund the commercialization of Astute’s first product and the continued development of the pipeline. “That’s right.
“We believe that the successful completion of this funding reflects the tremendous progress made so far in our research, development and clinical activities,” said Christopher Hibberd, Astute Medical Chief Executive Officer. “We are pleased to have the confidence of an outstanding group of life science-oriented investors and believe that we are well positioned to build a strong, sustainable pipeline of high-utility diagnostic products. “That’s right.
Additional funding participants included existing shareholders De Novo Ventures, Delphi Ventures, Domain Associates and Johnson & Johnson Development Corporation.
Astute Medical, Inc. Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases by identifying and validating protein biomarkers that may serve as the basis for novel diagnostic tests. The company focuses on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Current areas of interest for Astute Medical include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. For more information, please visit